| Today’s Big NewsNov 16, 2023 |
| By Kevin Dunleavy Vertex and CRISPR Therapeutics have scored authorization in the U.K. for their exa-cel gene therapy to treat patients with sickle cell and transfusion-dependent beta thalassemia. Despite the excitement for the anxiously awaited drug—which Vertex said will potentially open the treatment up to 2,000 patients in the U.K.—a key question remains: Because of its steep price, will it ever be commercialized in England? |
|
|
|
By Annalee Armstrong Almost a year to the day after Roche revealed that its Alzheimer's drug gantenerumab failed a phase 3 trial, the data are appearing in The New England Journal of Medicine, giving scientists a chance to reflect on what was learned. |
By Annalee Armstrong Fierce Biotech investigates a biotech caper after Takeda's TAK-279 poster mysteriously went missing from the late-breaker poster session at ACR in San Diego this week. |
By Andrea Park In its second and third such notices this week, the FDA doled out its most serious label to recalls of syringe devices used in medication delivery. |
By Angus Liu Watch out, Pfizer and Roche. Thanks to an acquisition and now an FDA approval, Bristol Myers Squibb is entering a niche lung cancer market. |
By Gabrielle Masson Merck & Co. is running out of time to get the first chronic cough medicine to market. So far, its path has been wrought with delays and the future appears no different as the FDA expresses new doubt about the pharma’s candidate gefapixant. |
By Conor Hale The over-the-counter Simple 2 test is sold by LetsGetChecked—a former Fierce 15 winner that made a name for itself in remote testing during the COVID-19 pandemic. |
By Nick Paul Taylor Astellas has shared a detailed look at the four deaths in its AT132 gene therapy clinical trial. Writing in The Lancet Neurology, the drugmaker explained that the liver toxicity seen in the trial differs from cases linked to other therapies—and made the case that the drug can provide transformative clinical benefits. |
By Fraiser Kansteiner The Gates Foundation blessed Micron with a $23.6 million grant to built out a commercial manufacturing facility for the company’s dissolvable, microarray-based drug and vaccine delivery tech. |
By Conor Hale According to the San Francisco-based company, sepsis contributes to more than one third of all in-hospital deaths—more than 350,000 annually in the U.S. |
By Andrea Park Less than a year after absorbing fellow virtual reality-based digital therapeutics maker OxfordVR, BehaVR is bulking up its business through yet another merger. |
Fierce podcastsDon’t miss an episode |
| | In this week’s episode of "Podnosis," you'll hear from two journalists from the Fierce Healthcare team: Paige Minemyer, senior editor of Fierce Health Payer, and Dave Muoio, a staff writer for Fierce Healthcare. Together, they guide you through their key insights from the inaugural Fierce Health Payer Summit in Austin and dive into the latest earnings updates from the largest health plans and health systems. |
|
|---|
|
|
|
Tuesday, November 28, 2023 | 11am ET / 8am PT Elevate your biopharmaceutical game! Join our webinar to explore game-changing solutions. Uncover the power of Recombumin® rHA – the consistent, animal-free alternative revolutionizing manufacturing. Don't miss this chance to stay ahead in the advanced therapy landscape.
|
|
| Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
| WebinarWatch now to explore the convergence of science, capital, operational excellence and workplace strategy. Sponsored by: JLL |
| Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperDownload our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications. Sponsored by: Aldevron, a GMP manufacturing CDMO of DNA, RNA, and Proteins |
| WhitepaperThis paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders. Presented by Blue Matter, strategic consultants in the life sciences |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| WhitepaperAccelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| |
|
